View of Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison | Drug Target Insights

Return to Article Details Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison